Amarin Corp Plc (AMRN)

[sts66]

Hikma cannot challenge R-IT patents before ANDA exclusivity ends this Dec, then there's a 30 month stay before FDA will accept an ANDA challenging R-IT patents. All Hikma can argue is whether they are infringing R-IT patents or not, cannot argue the patents are invalid - to do otherwise would allow them to bypass that 30 month hurdle.